abdominal fat mass, concomitant with the enhanced CPT activities in white adipose tissue, brown adipose tissues and muscle in OLETF rats (9, 10) . We observed enhanced energy expenditure after CLA feeding in obese rats.
The liver is the main organ in which lipid and lipoprotein metabolism occurs. Some studies suggest that dietary CLA increases hepatic lipid contents in mice, and concomitant decreases body fat mass (6) (7) (8) , although it is not so clear whether these results can extrapolate to rats and humans. Hence, we investigated the effects of CLA on hepatic lipid content and lipid metabolism in an obese model animal, OLETF rats, which are known to be prone to non-insulin dependent diabetes mellitus (NIDDM), and to show hypertriglyceridemia and hyperinsulinemia (11) (12) (13) . The effects of the two CLA forms on serum concentrations of lipids, glucose, insulin, leptin and TNF-a were also compared.
Materials and Methods

1 Animal Experiment and Diet Composition
Both male OLETF and Long-Evans Tokushima Otsuka (LETO; wild lean type) rats of 5-wk old (B.W. 135-140 g) were supplied from Tokushima Research Institute of Otsuka Pharmaceutical Co. Ltd., (Tokushima, Japan). Rats were housed individually in metal cages in a temperature-controlled room under 12 h light/dark cycle. After one week adaptation period, the rats were divided into groups and given the following diets ( Table 1) ; control diet (both LETO and OLETF control): 6.5% safflower oil, 1% TAG-CLA diet: 1% TAG-CLA+5.5% safflower oil, 1% FA-CLA diet: 1% FA-CLA+5.5% safflower oil. Both form of CLAs and safflower oil were supplied by Rinoru Oil Mills Co., Ltd. (Nagoya, Japan). The mass of total 18:2 in each diet was almost identical and the CLAs provided as TAGform and FA-form contained same isomers (33.2% c-9, t-11/t-9, c-11-CLA, 34.2% t-10, c-12 and other CLA isomers and fatty acids) ( Table 2) . After the experimental period for 4 weeks being over, the rats were sacrificed after 10 h fasting and blood was taken from venacava. Serum was separated by centrifuging blood at 3000 rpm for 15 min. Livers were excised and stored at 80 . The animal experiment was conducted according to the guideline provided by the ethical committee of experimental animal care at Saga University.
Preparation of Liver Subcellular Frac-
tions Liver homogenates and subcellular fractions were prepared as described previously (14) . A piece of liver was homogenized in 4 volume of ice-cold 0.25 M sucrose homogenate solution containing 1 mM EDTA, 0.2 mM dithiothreitol and 10 mM Tris-HCl (pH 7.4) buffer. After centrifuging to sediment nuclei, cell debris, and the mitochondrial fraction at 20,000 xg for 20 min at 4 , the resulting supernatant was recentrifuged at 105,000 g for 45 min at 4 to sediment microsomes, and the remaining supernatant being used as the cytosolic fraction. Microsomal pellet was resuspended with a small volume of the homogenate buffer solution. The fractions were stored at 80 . Protein was assayed by the method of Lowry et al. (15) using bovine serum albumin as a standard.
3 Lipid Analysis
Lipids were extracted and purified by the method of Folch et al. (16 
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and cholesterol were measured by the method of Fletcher (17) , and Sperry and Webb (18) , respectively. The hepatic phospholipid was quantified by phosphorus content as reported previously (14) . The total cholesterol, HDL-cholesterol, TAG and phospholipid in serum were measured enzymatically with commercial kits supplied by Wako Pure Chemical Ind. (Osaka, Japan) following the procedure supplied.
4 Assays of Enzyme Activity
The activities of CPT and PAP, and protein concentration were measured as described in the previous study (14) .
CPT (EC2.3.1.23) activity was assayed by measuring the CoA-SH formation. The reaction mixture contained 116mM Tris HCL (PH=8.0), 2.50 mM EDTA neutralized to PH 8.0 with Tris, 2.50 mM L-carnitine, 0.50 mM DTNB, 75mM palmitoyl-CoA and 0.2% Triton-X 100. The whole solution was equilibrated at 25 . The reaction was initiated by addition of enzyme source and the absorbance was monitored for 2-4 min. the L-carnitine independent rate was determined in a second cuvette by only omitting L-carnitine. The difference between with and without L-carnitine gave the L-carnitine dependent rate for formation of CoA-SH. The assay was conducted in freeze-thawed homogenate.
PAP (EC 3.1.3.4) activity was assayed by the method of Possmayer and Walton with slight modification (19) . The reaction mixtures contained 0.05 M Tris-HCl (pH 7.0), 1 mM L-a-phophatidate and 1 mM phosphatidylcholine liposomes suspended in 1.55 M sodium chloride, in the presence of 1.25 mM magnesium sulfate, and 50 to 100 mg of liver enzyme protein in a final assay volume of 0.2 ml. The mixture was incubated for 15 min at 37 and reaction was terminated by the addition of 0.8 ml of a solution containing 0.13% sodium dodecyl sulfate, 1.25% ascorbic acid, 0.32% ammonium molybdate-4H 2 O and 0.75 N H 2 SO 4 and the liberated inorganic phosphate was measured. The phosphomolybdate color was developed at 45 for 20 min and the absorbance was measured at 820 nm. Non-enzymatic phosphate release was determined by inactivating the enzymes by boiling for 1 min without substrate. The enzyme activity expressed as nanomole in one minute per mg protein.
Glucose-6-phosphate dehydrogenase (G6PDH; EC 1.1.1.49) activity was measured as previously described (20) . The reaction solution contained 0.32 M Tris-HCl (pH 7.6), 50 mM MgCl 2 , 66 mM glucose-6-phosphate, 24 mM NADP + , 1unit 6-phosphogluconate dehydrogenase. The reaction solution was preincubated at 27 , and the reaction was initiated by adding of cytosol (250 mg protein) in a final assay volume of 3.0 ml at 27 for 2 min. The absorbance was determined at 340 nm. G6PDH activity was expressed as nanomole of enzyme produces NADPH/min/mg protein.
Malic enzyme (ME; EC 1.1.1.40) activity was determined as previously described (21) . The reaction solution contained 0.4 M triethanolamine (pH 7.4), 30 mM malic acid, 0.12 M MnCl 2 and 3.4 mM NADP + . The reaction solution was preincubated at 27 , and the reaction was initiated by adding of cytosol (250 mg protein) in a final assay volume of 3.0 ml at 27 for 2 min. The absorbance was determined at 340 nm. Malic enzyme activity was expressed as nanomole of enzyme produces NADPH/min/mg protein.
5 Assays of Serum Concentrations of
Insulin, Glucose, Leptin and TNF-a Serum insulin concentration was determined with a radioimmunoassay kit (Linco, St. Charles, MO) standardized against rat insulin. Serum leptin concentration was determined with a radioimmunoassay kit (Linco, St. Charles, MO) for specifically determining rat leptin. The glucose in serum was measured enzymatically with commercial kits supplied by Wako Pure Chemical Ind. (Osaka, Japan) following the procedure supplied. Serum TNF-a concentration was determined with a rat TNF-a ELISA kit supplied by Wako Pure Chemical Ind. (Osaka, Japan) following the procedure supplied.
6 Statistical Analyses
Each value is presented as means SE. Data were analyzed by one-way ANOVA, all differences being inspected by Duncan's new multiple-range test (22) . A difference was considered significant at p<0.05. mg/g liver) were markedly higher in OLETF controls than in LETO rats (Fig. 1) . Administration of TAG-CLA significantly reduced hepatic TAG content compared to the OLETF controls (Fig. 1) . The same level of reduction in TAG was observed in the FA-CLA group. No significant effects were seen, however, with either CLA diet on hepatic cholesterol or phospholipid content.
Results
1 Lipid Concentrations in the Liver
2 Serum Concentrations of Lipids
Serum TAG level was higher in the OLETF rats compared to the LETO rats. Treatment with both forms of CLAs lowered TAG concentration compared to the corresponding controls (Fig. 2) . There were no significant differences in serum cholesterol and phospholipid levels between the OLETF groups.
Serum Concentrations of Glucose,
Insulin, Leptin and TNF-a Serum concentrations of glucose, insulin, leptin and TNF-a were higher in the OLETF controls in comparison to LETO controls, as shown in Fig. 3 . Dietary TAG-CLA had no significant influence on serum concentrations of glucose and insulin, although the latter tended to be lower than in the corresponding controls. FA-CLA raised the serum glucose level, although serum insulin levels were comparable to the controls. Serum leptin concentration was lower in both CLA groups in comparison to controls. TNF-a levels were comparable between these groups.
4 Activities of Enzymes Involved in Lipid
Metabolism Hepatic CPT activity is shown in Fig. 4 . CPT activity was lower in OLETF rats than in LETO rats, suggesting decreased fatty acid oxidation in these obese rats. A similar and significant enhancement of CPT activity (approximately 2-fold) was observed in both CLA groups compared to controls. There were no significant differences in microsomal PAP activity between the groups. ME and G6PDH activities were comparable between the OLETF groups, although administration of CLA tended to increase those activities. 
Comparison of the Physiological Effects of TAG-CLA and FA-CLA
Discussion
The present study aimed to compare the effects of TAG-CLA and FA-CLA on liver lipid metabolism and serum metabolites in OLETF obese rats, witch are known to be prone to NIDDM and have hypertriglyceridemia at an early stage and hyperinsulinemia in adulthood (11) . As reported previously, serum concentrations of lipids, glucose, insulin, leptin and TNF-a toward to be higher in OLETF rats in comparison to LETO controls (Fig. 2, 3) .
Earlier, we found that administration of CLA to male OLETF rats caused a reduction in abdominal fat tissue mass, which it was associated with enhancement of CPT activity in adipose tissue and muscle (9, 10), and increased energy expenditure (23) . The liver is the central organ regulating lipid and lipoprotein metabolism, but little is known about the effect of CLA on liver lipid metabolism. Hepatic TAG metabolism is regulated by fatty acid synthesis and oxidation and lipoprotein secretion. Results of the present study revealed that TAG-CLA and FA-CLA reduce hepatic TAG mass significantly (Fig. 1) , although hepatic concentrations of cholesterol and phospholipid were comparable between groups. CLA therefore has the ability to reduce both hepatic and serum TAG levels. The findings are in contrast with the earlier reports in which CLA accumulated TAG in mouse liver (24) . The reasons for these differences may be species-specific. In this context, no evidence of hepatic injury or fatty liver has been reported with the supplementation of CLA in humans (25, 26) .
In the present study, enhancement of hepatic CTP activity was seen by the treatment of both forms of CLA (Fig. 4) . As CPT is a key enzyme necessary for fatty acid oxidation (13), these results suggest stimulation of fatty acid oxidation in the liver. In contrast, there were no significant changes in the activities of hepatic PAP, ME and G6PDH, indicating that CLA did not affect the synthesis of fatty acid and TAG in the liver. Some studies reported that CLA inhibited the hepatic activity of stearoyl-CoA desaturase (27, 28) , a key enzyme in the desaturation of stearic acid to oleic acid. The present results suggest that CLA may directly affect fatty acid oxidation rather enhancing esterification process. Increased beta-oxidation may ultimately prevent the storage of TAG in the liver and adipose tissues. There are several possible mechanisms by which CLA may induce increased CPT activity. One proposed mechanism is that CLA modulates lipid metabolism, in part by a mechanism dependent on the activation of the group of nuclear transcriptional factors, peroxisome proliferator-activated receptors (PPARs) (29) . In the liver, PPARa is thought to be a critical transcriptional factor for lipid metabolism, because several genes coding for enzymes involved with b-oxidation contain a functional peroxisome proliferator-responsive element in their enhancer regions (30) . Several isomers of CLA are in fact high affinity ligands and activators of PPARa (31) , and PPARa is thought to play a role in the ability of CLA to modulate lipid metabolism (32, 33) . Recently, studies in PPARa-null mouse suggested, however, that PPARa may not be critical for lipid metabolism, because PPARa null mice fed a diet containing CLA had similar responses in comparison to the wild type, including CLA-dependent reduction of adiposity and induction of some PPAR-responsive genes in the liver (34) . It is therefore likely that CLA also modulates lipid metabolism via PPARa-independent mechanisms. Earlier, we showed that10t,12c-CLA isomer reduced apoprotein B100 secretion in cultured hepatoma HepG2 cells (35) . This is supported by the observation that serum TAG is lowered significantly by CLA in this study. We also observed that dietary CLA inhibits liver MTP activity (Wang et al., in press ). These data suggest that CLA reduces TAG mass and inhibits MTP activity in the liver, which results in lower serum TAG concentrations.
It has been reported that the onset of diabetes was delayed by CLA in the Zucker diabetes fatty rat model (36) . A recent study demonstrated that CLA enhanced glucose uptake in muscle in Zucker diabetes fatty rats (37) . We were unable, however, to detect any influence of TAG-CLA on serum fasting glucose level, but TAG-CLA showed a tendency to reduced insulin levels in the present study, as shown in Fig. 3 . In addition, FA-CLA modestly increased serum glucose levels. Hence, it is likely that different forms of CLA have different effects on fasting glucose in OLETF rats. It was reported that CLA reduces fasting insulin levels in diabetic animals, but enhances fasting insulin concentration in mice, pigs and humans (24, 38, 39) . TNF-a is associated with insulin resistance and abdominal obesity in humans (40) . In the present study, TAG-CLA had no significant effect on serum TNF-a levels, although FA-CLA tended to increase TNF-a levels. Further work is needed to explore the effects of the forms of CLA forms on these metabolic parameters.
In conclusion, both TAG-CLA and FA-CLA reduced hepatic and serum TAG concentrations in OLETF obese rats to similar degrees, which was associated with enhanced CTP activity. This suggests that TAG-CLA and FA-CLA have same ability to reduce liver and serum TAG levels, but the effects on serum glucose levels were different: TAG-CLA had no effect but FA-CLA raised serum glucose levels.
